Clinical Trial Update: Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating nilotinib and imatinib mesylate in early chronic phase chronic myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Imatinib mesylate (Imatinib)
• Nilotinib (nilotinib)

Snippet

Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto | Conditions: Leukemia | Phase 2 | Status: COMPLETED